Sequence sPecific ELImination of shiga-Toxin E. Coli

Project description

A pioneering antibiotic against toxic bacteria enters clinical trials

Escherichia coli (E. coli), a diverse group of bacteria normally found in the intestines, are mostly harmless while some are gut-friendly and beneficial to our health. However, among them, Shiga toxin-producing E. coli (STEC) are most commonly linked to foodborne outbreaks. Currently, treatment addresses only symptoms but not the cause of the illness. This may soon change thanks to the EU-funded SPELITEC programme as preclinical and clinical trials of a potent STEC eliminator will soon be underway. The drug stop STEC in its tracks without the release of the toxin into the intestines. Even better, it does not affect normal intestinal microorganisms or induce antibiotic resistance.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• natural sciences › biological sciences › microbiology › bacteriology
• natural sciences › biological sciences › genetics › mutation
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

ELIGO BIOSCIENCE

Net EU contribution

€ 2 763 775,00

Address

29 Rue Faubourg Saint Jacques Pepin
75014 Paris
France

Region

Ile-de-France › Ile-de-France › Paris

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 2 763 775,00